5CV.DE Stock Bounces 0.72% on May 12 as CureVac Finds Support

CureVac N.V. (5CV.DE) is showing signs of recovery on the XETRA exchange today. The German biotech company’s stock gained 0.72%, trading at €3.91 as of May 12, 2026. This modest bounce comes after the stock faced significant pressure in recent months, with shares down 15.27% over the past three months. The company, headquartered in Tübingen, focuses on developing mRNA-based vaccines and cancer immunotherapies. With a market cap of €879.5 million and trading volume at 125,272 shares, 5CV.DE stock is attracting renewed attention from investors watching for oversold recovery opportunities in the healthcare sector.

5CV.DE Stock Price Action and Technical Setup

CureVac’s stock opened at €3.896 and reached an intraday high of €3.96, establishing a narrow trading range. The day low of €3.862 shows support forming near current levels. Over the past year, 5CV.DE has gained 12.89%, but the three-year decline of 61.97% reflects the biotech sector’s volatility and the company’s clinical-stage challenges.

The stock trades well below its 52-week high of €4.90, suggesting room for recovery if sentiment improves. Volume at 125,272 shares represents 74.5% of the average daily volume, indicating moderate interest. The P/E ratio of 6.85 appears attractive compared to healthcare sector averages, though investors should note this reflects the company’s early-stage profitability profile.

Meyka AI Rating and Valuation Metrics

Meyka AI rates 5CV.DE with a grade of B+, suggesting a Buy recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating reflects mixed signals: strong ROE of 18.4% and ROA of 11.3% indicate efficient capital use, while the DCF score of 1 signals valuation concerns.

The stock trades at 1.01x book value, near fair value on a price-to-book basis. However, the price-to-sales ratio of 12.43 is elevated for a clinical-stage biotech company with limited revenue. Cash position remains solid at €1.86 per share, providing runway for ongoing R&D. These grades are not guaranteed and we are not financial advisors.

Pipeline Progress and Revenue Growth Drivers

CureVac is advancing multiple mRNA vaccine candidates through clinical trials. CV2CoV targets SARS-CoV-2, CV7202 addresses rabies, and CVSQIV targets influenza. The company also develops cancer immunotherapy CV8102 for melanoma and other solid tumors. Revenue grew 8.96% year-over-year, demonstrating progress despite clinical-stage status.

The company reported €0.57 EPS with net income per share of €0.57, showing profitability on a trailing basis. R&D spending represents 2.19x revenue, reflecting heavy investment in pipeline development. With 8,250 full-time employees, CureVac maintains substantial infrastructure to support multiple programs. Gross margin of 93% indicates strong unit economics when revenue scales.

Market Sentiment and Oversold Bounce Dynamics

Trading Activity: The intraday bounce reflects typical oversold recovery behavior after recent weakness. Volume remains below average, suggesting cautious participation rather than conviction buying. The €0.028 gain represents a technical bounce from support levels rather than fundamental catalyst-driven movement.

Liquidation Pressure: Negative cash flow metrics show -€0.56 free cash flow per share, indicating the company burns cash to fund operations. However, the current ratio of 3.70 demonstrates strong liquidity to cover near-term obligations. The debt-to-equity ratio of 0.04 is minimal, reducing financial stress. Investors should monitor quarterly cash burn rates as a key metric for sustainability.

Final Thoughts

CureVac (5CV.DE) gained 0.72% to €3.91, earning a B+ rating from Meyka AI. The stock balances strong profitability and cash reserves against clinical-stage risks and negative free cash flow. Its mRNA pipeline targets large markets but depends on trial outcomes and regulatory approval. Valuation near book value suits risk-tolerant biotech investors. Key metrics to monitor include quarterly cash burn, pipeline announcements, and sector trends. Clinical development timelines remain unpredictable.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.